[Evaluation of the role of chemotherapy adjuvant to surgery in patients with cancer of the ovary, 1st stage].
The paper discusses the results of a retrospective analysis of the data on the evaluation of the efficacy of chemotherapy as an adjuvant to surgery performed in 167 patients with stage I ovarian cancer who were treated at the Institute and Oncological Dispensary in the city of Gomel in 1963-1979. The evaluation was based on the comparison of 5-year survival rates and the frequency of recurrences in the following three study groups: surgery, surgery + chemotherapy and surgery + chemotherapy + prophylactic chemotherapy. It was found that chemotherapy courses given within 2.5-3 years after primary treatment are followed by a nearly two-fold (1.9) drop in recurrence frequency and a 16.6% increase in 5-year survival.